Abstract: The present invention relates to an improved process for the preparation of Valacyclovir or pharmaceutically acceptable salts thereof, which comprises reaction of amine-protected Valacyclovir or its salt with deprotecting agent in a continuous flow reactor.
Abstract: Compound (I), and pharmaceutically acceptable salts thereof, are inducers of human interferon. Certain discrete and particular dosages of Compound (I) may be particularly useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and allergic asthma.
Type:
Application
Filed:
September 27, 2018
Publication date:
January 24, 2019
Inventors:
Claire Louise AMBERY, Christopher David EDWARDS
Abstract: Compounds of formula (I): where R1, R2, R3, R4a, R4b, R5, R6 and R7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.
Type:
Application
Filed:
September 12, 2018
Publication date:
January 24, 2019
Inventors:
Lloyd F. Mackenzie, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew
Abstract: The present invention provides novel compounds of any one of Formulae (I)-(IV), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of any one of Formulae (I)-(IV) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor signaling pathway (e.g., vascular endothelial growth factor (VEGF), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.
Type:
Application
Filed:
June 21, 2018
Publication date:
January 24, 2019
Inventors:
Winston Zapanta Ong, Pawel Wojciech Nowak, Ben C. Askew, Andrew Good
Abstract: The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.
Type:
Application
Filed:
July 27, 2018
Publication date:
January 24, 2019
Inventors:
Hamid R. Hoveyda, Guillaume Dutheuil, Graeme Lovat Fraser, Marie-Odile Roy, Mohamed El Bousmaqui, Frederic Batt
Abstract: The present application falls within the field of drug synthesis, and in particular, the present application relates to a method for preparing ruxolitinib, and a method for preparing the intermediate and relevant intermediates used. The method comprises reacting a compound of formula II with a compound of formula IV or a salt thereof to obtain a compound of formula III, and then subjecting the compound of formula III to an acyl halogenation reaction, an amidation reaction, and a reaction dehydrating an amide to form a cyano group or removing the protecting group to prepare ruxolitinib. The method has the characteristics of brief steps, a high stereoselectivity, a high utilization ratio of atoms, mild reaction conditions and convenient post treatment. The method avoids using expensive asymmetric reaction catalysts, and is suitable for industrial production.
Abstract: The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.
Type:
Application
Filed:
January 5, 2017
Publication date:
January 24, 2019
Inventors:
Jérôme Émile Georges GUILLEMONT, Wendy Mia Albert BALEMANS, David Craig MC GOWAN, Magali Madeleine Simone MOTTE, David Francis Alain LANÇOIS, Emilie Marie LAMBERT
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Type:
Application
Filed:
February 7, 2018
Publication date:
January 24, 2019
Inventors:
Ayman ALLIAN, Jayanthy JAYANTH, Mohamed-Eslam F. MOHAMED, Mathew M. MULHERN, Lars Fredrick NORDSTROEM, Ahmed A. OTHMAN, Michael J. ROZEMA, Lakshmi BHAGAVATULA, Patrick J. MARROUM, Peter T. MAYER, Ahmad Y. SHEIKH, Thomas B. BORCHARDT
Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
Type:
Application
Filed:
September 27, 2018
Publication date:
January 24, 2019
Inventors:
Zehong WAN, Xiaomin ZHANG, Jian WANG, Matthew Robert SENDER, Eric Steven MANAS, Raphael Anthony RIVERO, Joseph E PERO, Christopher Ernst NEIPP, Vipulkumar Kantibhai PATEL
Abstract: Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
Type:
Application
Filed:
March 15, 2018
Publication date:
January 24, 2019
Inventors:
Robert Zahler, Zhenwei Cai, Zhixing Wu, James E. Vath
Abstract: In one aspect, the present invention provides novel derivatives of trioxacarin analogs of the formula (I) wherein the variables are as defined herein. The application also provides compositions, methods of treatment, and methods of synthesis thereof.
Abstract: The present invention relates to novel crystalline forms of dolutegravir, process for its preparation and pharmaceutical composition comprising them.
Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
Type:
Application
Filed:
September 25, 2018
Publication date:
January 24, 2019
Inventors:
Douglas G. Batt, Myra Beaudoin Bertrand, George V. De Lucca, Michael A. Galella, Soo Sung Ko, Charles M. Langevine, Qingjie Liu, Qing Shi, Anurag S. Srivastava, Joseph A. Tino, Scott Hunter Watterson
Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
Type:
Application
Filed:
September 5, 2018
Publication date:
January 24, 2019
Applicant:
Amgen Inc.
Inventors:
Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S, LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
Abstract: Gold(III) complexes containing mixed ligands. A method of treating cancer with these complexes is disclosed. The complexes are cytotoxic to prostate, breast, ovarian, and Hodgkin lymphoma cancer cell lines. These complexes were either more potent than cisplatin or had similar potency to cisplatin.
Type:
Application
Filed:
July 20, 2017
Publication date:
January 24, 2019
Applicant:
King Fahd University of Petroleum and Minerals
Inventors:
Anvar Husain Abdul Kadir ISAB, Muhammad Altaf
Abstract: PSMA-targeted PET/SPECT agents for imaging PSMA-positive cancer and or tumor neovasculature and PSMA-targeted radiotherapeutic agent for the treatment of PSMA-positive cancer or tumor neovasculature are disclosed. Methods of imaging PSMA expressing tumors, or cells and kits also are disclosed.
Type:
Application
Filed:
March 14, 2016
Publication date:
January 24, 2019
Applicant:
THE JOHNS HOPKINS UNIVERSITY
Inventors:
MARTIN G. POMPER, RONNIE C. MEASE, SANGEETA RAY
Abstract: The present invention relates to compositions comprising at least one hydridosilane of the generic formula SinHm with n?5 and m=(2n) and (2n+2) and at least one compound of the formula HnB (OR)3-n with R=C1-C10-alkyl, C6-C10-aryl, C7-C14-aralkyl, halogen, n=0, 1, 2, to processes for preparation thereof and use thereof.
Type:
Application
Filed:
December 6, 2016
Publication date:
January 24, 2019
Applicant:
Evonik Degussa GmbH
Inventors:
Stephan HERRMANN, Odo WUNNICKE, Matthias PATZ, Miriam Deborah MALSCH, Harald STUEGER
Abstract: The present invention relates to process for preparation of tavaborole with high purity. The present invention relates to method of assessing the purity of tavaborole.
Abstract: The present invention relates to a modifier, and more particularly, to a modifier including a compound represented by Formula 1, a method of preparing the same, and a modified conjugated diene-based polymer including the same. The present invention also provides a modifier exhibiting excellent dispersibility via hydrogen bonding with an inorganic filler when mixed therewith, a method of preparing the same, a modified conjugated diene-based polymer modified using the modifier and thus exhibiting excellent processability, high tensile strength, high wear resistance, low rolling resistance, and high wet skid resistance, and a method of preparing the modified conjugated diene-based polymer.
Type:
Application
Filed:
September 5, 2017
Publication date:
January 24, 2019
Applicant:
LG Chem, Ltd.
Inventors:
Min Sik Mun, No Ma Kim, Da Won Chai, Ho Young Lee
Abstract: The purpose of the present invention is to provide a protecting group which improves the solubility of a compound having a functional group protected with the protecting group in an organic solvent and which is easily separated and purified after a reaction with avoiding solidification or insolubilization.
Abstract: A method for preparing a 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivative by a simple process with high yields, and an intermediate useful for the method.
Type:
Application
Filed:
January 13, 2017
Publication date:
January 24, 2019
Applicant:
YONSUNG FINE CHEMICAL CO., LTD.
Inventors:
Hyun Ik SHIN, Kee Young LEE, Changyoung OH
Abstract: Provided are a polyhedral oligomeric silsesquioxane and a preparation method thereof, more particularly, a polyhedral oligomeric silsesquioxane itself which has a low refractive property and enables formation of a coating layer with excellent chemical and mechanical properties, and provides excellent adhesive strength for the surfaces of various substrates, and a preparation method thereof.
Type:
Application
Filed:
March 9, 2017
Publication date:
January 24, 2019
Applicant:
LG Chem, Ltd.
Inventors:
Ji Young Choi, Dai Seung Choi, Young Jee Song
Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
Type:
Application
Filed:
September 24, 2018
Publication date:
January 24, 2019
Applicant:
Achillion Pharmaceuticals, Inc.
Inventors:
Jason Allan Wiles, Venkat Rao Gadhachanda, Qiuping Wang, Godwin Pais, Akihiro Hashimoto, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke
Abstract: Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy.
Type:
Application
Filed:
June 26, 2018
Publication date:
January 24, 2019
Inventors:
Brian S.J. BLAGG, Bhaskar Reddy KUSUMA, Teather SUNDSTROM
Abstract: The invention described herein relates to processes for preparing ketolide antibacterial agents. In particular, the invention relates to intermediates and processes for preparing ketolides that include a 1,2,3-triazole substituted side chain.
Abstract: The present invention relates to novel oligonucleotides comprising at least one locked nucleoside and at least one triazole inter-nucleoside linkage.
Type:
Application
Filed:
July 17, 2018
Publication date:
January 24, 2019
Inventors:
Tom BROWN, Afaf Helmy EL-SAGHEER, Pawan KUMAR
Abstract: The present invention relates to compounds characterized by having a structure according to the following Formula I: or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.
Abstract: Disclosed herein are formulations, substrates, and arrays for amino acid and peptide synthesis on microarrays. In certain embodiments, methods for manufacturing and using the formulations, substrates, and arrays including one-step coupling, e.g., for synthesis of peptides in a C?N orientation are disclosed. In some embodiments, disclosed herein are formulations and methods for high efficiency coupling of biomolecules to a substrate.
Abstract: The invention discloses a separation matrix which comprises a plurality of separation ligands, defined by the formula R1-L1-N(R3)-L2-R, immobilized on a support, wherein R1 is a five- or six-membered, substituted or non-substituted ring structure or a hydroxyethyl or hydroxypropyl group; L1 is either a methylene group or a covalent bond; R2 is a five-or six-membered, substituted or non-substituted ring structure; L2 is either a methylene group or a covalent bond; R3 is a methyl group; and wherein if R1 is a hydroxyethyl group and L1 is a covalent bond, R2 is a substituted aromatic ring structure or a substituted or non-substituted aliphatic ring structure.
Type:
Application
Filed:
August 29, 2018
Publication date:
January 24, 2019
Applicant:
GE Healthcare BioProcess R&D AB
Inventors:
Jean-Luc Maloisel, Gustav Rodrigo, Bjorn Noren, Virendra Kumbhar
Abstract: The present invention provides a method for purifying a protein, comprising: providing a solution containing a monomer and aggregates of the protein of interest; a purification step of removing the aggregates of the protein of interest using a cation-exchange chromatographic support media to obtain a purified solution of the monomer, the cation-exchange chromatographic support media comprising at least one type of weak cation-exchange group and having a cation-exchange group density higher than 30 mmol/L; and a virus removal step of removing viruses from the purified solution using a virus removal membrane having a virus logarithmic reduction value of 3 or more.
Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
Type:
Application
Filed:
March 8, 2018
Publication date:
January 24, 2019
Inventors:
Rene M. Lemieux, Janeta Popovici-Muller, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of phenazine-3-one and/or phenothiazine-3-one derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to phenazine-3-one or phenothiazine-3-one derivatives and uses of the same. In some embodiments, the aromatic-cationic peptide comprises D-Arg-2?6?-Dmt-Lys-Phe-NH2.
Abstract: The present invention provides peptides containing a structure in which a portion of the dominant negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 is substituted with stapling structure(s). Peptides of the present invention have excellent cell growth inhibitory actions. Furthermore, their cell growth inhibitory actions continue for a longer time than the actions of peptides without stapling structures. Therefore, these peptides have features suitable for clinical applications in cancer therapy.
Type:
Application
Filed:
January 16, 2017
Publication date:
January 24, 2019
Applicants:
TOKUSHIMA UNIVERSITY, ONCOTHERAPY SCIENCE, INC.
Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.
Abstract: The present invention provides a novel molecule that catalyzes a hydrolysis reaction and is different from enzyme proteins. The catalytic peptide according to the present invention is a catalytic peptide that catalyzes a hydrolysis reaction, including at least one peptide selected from the group consisting of the following peptides (A1) to (A4): (A1) a peptide consisting of Box A and at least one of an upstream region and a downstream region therefrom in a Tob/BTG protein; (A2) a peptide consisting of a partial region of the peptide (A1); (A3) a peptide that consists of an amino acid sequence obtained by deletion, substitution, addition, and/or insertion of one or more amino acids in an amino acid sequence of the peptide (A1) or (A2) and has hydrolysis activity; and (A4) a peptide consisting of an amino acid sequence with a sequence identity of at least 85% to the amino acid sequence of the peptide (A1) or (A2) and having hydrolysis activity.
Abstract: Provided is a supramolecular polypeptide comprising alternating repeats of crystallite-forming subsequences and amorphous subsequences. The crystallite-forming subsequences form crystallites comprising stacks of one or more ?-sheets and the amorphous subsequences form a network of hydrogen bonds. The supramolecular polypeptides are capable of exhibiting self-healing behavior.
Type:
Application
Filed:
July 24, 2018
Publication date:
January 24, 2019
Inventors:
Melik Demirel, Benjamin Allen, Huihun Jung
Abstract: Drug-polymer chemotherapeutics are provided having improved therapeutic efficacy and reduced dose-limiting toxicity. Methods are also provided for modulating the architecture, pharmacokinetics and biodistribution of drug-polymers and for reducing the dependence of transition temperature on concentration for drug-polymers.
Type:
Application
Filed:
August 8, 2018
Publication date:
January 24, 2019
Inventors:
Ashutosh Chilkoti, John A. MacKay, Matthew R. Dreher
Abstract: Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.
Type:
Application
Filed:
July 19, 2018
Publication date:
January 24, 2019
Inventors:
Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Nika Mindy STROKAPPE, Daphné TRUAN
Abstract: The present invention methods and compositions for treating a Zika virus infection in a subject, comprising administering to the subject an effective amount of an antibody against Zika virus and/or an epitope that induces an immune response to Zika virus.
Type:
Application
Filed:
July 19, 2018
Publication date:
January 24, 2019
Inventors:
Ralph Baric, Jessica A. Plante, Jesica Swanstrom, Matthew Begley
Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain.
Type:
Application
Filed:
August 2, 2018
Publication date:
January 24, 2019
Inventors:
Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.
Type:
Application
Filed:
October 8, 2018
Publication date:
January 24, 2019
Inventors:
Luis Alejandro Hernandez, Christine Margaret Muehlenthaler, Eric Martin Vaughn, Gregory Haiwick
Abstract: The present invention relates to an RhtB (homoserine/homoserine lactone export transporter) protein variant having an enhanced ability to export O-phosphoserine (OPS) that is a precursor of L-cysteine, a polynucleotide encoding the protein, a vector comprising the polynucleotide, an OPS-producing microorganism comprising the protein variant, a method of producing O-phosphoserine using the microorganism, and a method for preparing cysteine or its derivatives, which comprises reacting O-phosphoserine, produced by the method above, with a sulfide in the presence of O-phosphoserine sulfhydrylase (OPSS) or a microorganism that expresses OPSS.
Type:
Application
Filed:
October 10, 2018
Publication date:
January 24, 2019
Applicant:
CJ CHEILJEDANG CORPORATION
Inventors:
Sol KIM, Hye Won KIM, Jin Sook CHANG, In Hwa YOO
Abstract: Bioactive priming polypeptides are provided that are useful when applied to plants in agricultural formulations. Methods of using the formulations containing the bioactive priming polypeptides are also provided which are applied exogenously to the surface of a plant or a plant cell membrane or endogenously to the interior of a plant or to a plant cell. The bioactive priming polypeptides when applied to a plant, a plant part, or a plant growth medium or a rhizosphere in an area surrounding the plant or the plant part increase growth, yield, health, longevity, productivity, and/or vigor of a plant or a plant part and/or decrease abiotic stress in the plant or the plant part and/or protect the plant or the plant part from disease, insects and/or nematodes, and/or increase the innate immune response of the plant or the plant part and/or change plant architecture.
Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.
Type:
Application
Filed:
October 10, 2018
Publication date:
January 24, 2019
Applicant:
Novozymes, Inc.
Inventors:
Kimberly Brown, Paul Harris, Elizabeth Zaretsky, Edward Re, Elena Vlasenko, Keith McFarland, Alfredo Lopez de Leon
Abstract: Yeast having modified chromsomes are provided. The chromosomes are modified such that at least one of yeast histones H3, H4, H2A or H2B are fully or partially replaced by their human histone counterparts H3, H4, H2A or H2B, respectively. Histone amino acid substitutions are included. Cell fusions with the yeast having the modified chromosomes and non-yeast cells are provided. Methods for screening test agents using the yeast are also provided. Yeast with a mutated yeast DAD1 gene, the mutated DAD1 gene encoding an E50D mutation in yeast DAD1 protein, are provided, and provide a useful genetic background for making the yeast with partially or fully replaced histone(s).
Abstract: This disclosure provides plants having enhanced traits such as increased yield, increased nitrogen use efficiency and increased water use efficiency; propagules, progeny and field crops of such transgenic plants; and methods of making and using such transgenic plants. This disclosure also provides methods of producing hybrid seed from such transgenic plants, growing such seed and selecting progeny plants with the composition or with enhanced traits.
Type:
Application
Filed:
March 26, 2018
Publication date:
January 24, 2019
Inventors:
Mark S. Abad, Paul S. Chomet, Dhanalakshmi Ramachandra, Tyamagondlu V. Venkatesh, Xiaoyun Wu
Abstract: Methods for treating cancer with a stabilized BCL9 peptide are encompassed, wherein the stabilized peptide comprises a portion of the HD2 domain of the BCL9 protein containing a hydrocarbon crosslinker generated using ?, ?-disubstituted amino acids.
Abstract: The invention provides peptides and analogs of INGAP and HIP peptides. The peptides and analogs can be used in methods for treating various diseases and conditions. Such diseases and conditions can include impaired pancreatic function, treating a metabolic disease, for example, diabetes, both type 1 and type 2 diabetes, islets induction, expansion and proliferation for transplantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibiting inflammation.